CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today the appointment of Donald E. Wallroth to the position of Chief Financial Officer. He joins Molecular Insight from the National Life Sciences practice of Tatum, LLC, an executive financial services firm. “We’re delighted to have an accomplished and seasoned executive of Don’s breadth and depth join our strong management team,” said David S. Barlow, Chairman and Chief Executive Officer of Molecular Insight. “Don’s extensive experience in financial reporting, Sarbanes-Oxley compliance, audit, capital raising and strategic planning, along with his knowledge of the life sciences industry, will enable him to make meaningful contributions to Molecular Insight in the immediate and long-term.”
